Daily Progesterone is Appropriate for This Patient
For a 45-year-old woman still having periods on menopausal hormone therapy, both cyclic and continuous daily progesterone regimens are acceptable options for endometrial protection—the choice depends primarily on whether she prefers to continue having monthly bleeding or achieve amenorrhea.
Understanding the Clinical Context
This patient is perimenopausal (still menstruating at age 45) and has been placed on hormone therapy, likely for vasomotor symptoms or other menopausal complaints. The key issue is endometrial protection, not whether she's technically "postmenopausal."
Both Regimens Provide Adequate Endometrial Protection
The guidelines are clear that in women with an intact uterus, a progestational agent must be added to estrogen to prevent endometrial hyperplasia and cancer 1. However, the administration schedule can be either:
Cyclic Progestin Regimen
- 10-14 days per month at adequate doses 1
- Produces predictable monthly withdrawal bleeding
- Preferred for recently menopausal women prone to breakthrough bleeding during the first year or two of therapy 2
Continuous Daily Progestin Regimen
- Daily administration without interruption
- Achieves amenorrhea in over 50% of women 3, 4
- Many women experience breakthrough bleeding initially, which typically resolves over time 1
Why Daily Progesterone Makes Sense Here
The continuous daily regimen is not contraindicated simply because she's still having periods. Here's the reasoning:
Persistent menstrual bleeding is the major reason for noncompliance with hormone therapy 1. If this patient wants to avoid monthly bleeding, continuous therapy is appropriate.
The goal is endometrial protection, not mimicking a natural cycle. Both regimens provide adequate protection when dosed correctly 1, 4.
Breakthrough bleeding with continuous therapy typically resolves by 5-6 months 4. Initial irregular bleeding doesn't indicate treatment failure.
Important Caveats and Monitoring
If Cyclic Therapy is Preferred:
- Use progestin for 10-14 days monthly (not less) 1
- Expect regular withdrawal bleeding
- Better tolerated initially in perimenopausal women 2
If Continuous Therapy is Continued:
- Any unexpected or persistent irregular bleeding requires endometrial evaluation with ultrasound and/or biopsy 1
- Have a low threshold for endometrial sampling as no clear bleeding patterns predict abnormal histology 1
- Consider switching to cyclic therapy if breakthrough bleeding persists beyond 6 months 5
Breast Cancer Considerations:
- Continuous combined therapy may carry higher breast cancer risk than cyclic regimens 1, though this remains somewhat controversial
- Long-cycle therapy (progestin 14 days every 3 months) has been proposed to reduce breast exposure but is not well validated 1
Clinical Decision Algorithm
Choose cyclic progestin if:
- Patient prefers predictable monthly bleeding
- Early perimenopause with irregular cycles
- History of persistent breakthrough bleeding on continuous therapy
Choose continuous daily progestin if:
- Patient desires amenorrhea
- Compliance concerns with cyclic dosing
- Willing to tolerate initial breakthrough bleeding
Switch from continuous to cyclic if:
- Persistent irregular bleeding beyond 6 months
- Patient preference changes
- Abnormal endometrial findings on evaluation
Bottom Line
The prescriber's choice of daily progesterone is medically sound and does not need to be changed solely because the patient is still menstruating. The decision should be based on the patient's bleeding preferences, tolerance of breakthrough bleeding, and individual risk factors. If she's tolerating the current regimen without problematic bleeding, continue it. If breakthrough bleeding is bothersome or persistent, consider switching to cyclic administration (10-14 days monthly) 1.